Analyst Reco. Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
167.50 ^USD	+1.58%		-1.30%	+36.01%

Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day

Analyst Reco.

Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	Dec. 10
Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	Nov. 24	MT
UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Raises Price Target to $188 From $163	Nov. 24	MT
Truist Adjusts Price Target on Jazz Pharmaceuticals Public to $220 From $205, Maintains Buy Rating	Nov. 19	MT
Deutsche Bank Raises Price Target on Jazz Pharmaceuticals to $210 From $173, Keeps Buy Rating	Nov. 18	MT
Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast…	Nov. 18
RBC Raises Price Target on Jazz Pharmaceuticals to $155 From $151, Keeps Outperform Rating	Nov. 06	MT
Morgan Stanley Lifts Price Target on Jazz Pharmaceuticals to $185 From $183, Keeps Overweight Rating	Nov. 06	MT
Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says	Oct. 20	MT
Morgan Stanley Raises Price Target on Jazz Pharmaceuticals to $180 From $167, Keeps Overweight Rating	Oct. 20	MT
Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	Oct. 09	MT
BofA Adjusts Price Target on Jazz Pharmaceuticals Public to $230 From $225	Oct. 09	MT
Deutsche Bank Raises Price Target on Jazz Pharmaceuticals to $173 From $170, Keeps Buy Rating	Oct. 03	MT
Jazz Pharma, Roche's combination therapy for lung cancer gets US approval	Oct. 02	RE
US FDA approves Jazz Pharma's therapy for lung cancer	Oct. 02	RE
Truist Raises Price Target on Jazz Pharmaceuticals to $205 From $200, Keeps Buy Rating	Aug. 28	MT
RBC Raises Price Target on Jazz Pharmaceuticals to $151 From $145, Keeps Outperform Rating	Aug. 28	MT
Deutsche Bank Adjusts Jazz Pharmaceuticals Public Price Target to $154 From $152, Maintains Buy Rating	Aug. 07	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $145 From $167, Keeps Outperform Rating	Aug. 06	MT
Jazz Pharmaceuticals Stock Offers Buying Opportunity After Slump, Deutsche Bank Says	Jul. 15	MT
Deutsche Bank Initiates Jazz Pharmaceuticals at Buy With $152 Price Target	Jul. 15	MT
RBC Lowers Price Target on Jazz Pharmaceuticals to $167 From $172, Keeps Outperform Rating	Jul. 07	MT
Morgan Stanley Cuts Price Target on Jazz Pharmaceuticals to $166 From $183, Keeps Overweight Rating	May. 07	MT
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating	Apr. 03	MT
UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145	Mar. 07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Analyst Reco.

Filters